Cinetredekin besudotox Granted FDA Orphan Drug Designation by US FDA for Treatment of GBM October 16, 2025
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement with QIMR Berghofer for a first-in-class PD-L1 degrader program October 16, 2025
TUKYSA Combination Significantly Improves PFS as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial October 16, 2025
TransCode Therapeutics to acquire Polynoma and use $25M funds by CK Life Sciences to advance TTX-MC138 into Ph 2 trial October 16, 2025
Ph 2 study of BND-22 (SAR444881) + anti-PD-1 therapy in IO-refractory NSCLC or IO-naive MSS-CRC or ovarian cancer to be initiated October 16, 2025
Ph 3 Trial of HANSIZHUANG + Chemo Meets Primary Endpoint in Neoadjuvant/ Adjuvant Gastric Cancer, Greenlighting Early NDA Submission October 16, 2025
